- Conditions
- Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Consolidation Therapy, Functional Magnetic Resonance Imaging, Gastrointestinal Endoscopy, Magnetic Resonance Imaging, Papaverine, Radiation Therapy, Total Mesorectal Excision
- Procedure · Drug · Radiation
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 841–864
of 878
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colon Adenocarcinoma, High-Frequency Microsatellite Instability, Metastatic Malignant Solid Neoplasm, Rectal Adenocarcinoma, Refractory Colorectal Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8
- Interventions
- Anti-PD-L1/TGFbetaRII Fusion Protein M7824
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer, Neoplasms, Colorectal
- Interventions
- CS7017, irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Fullerton, California • Washington D.C., District of Columbia + 3 more
- Conditions
- Rectal Cancer Surgery
- Interventions
- ColoSeal ICD System, Protective Diverting Ostomy
- Device · Procedure
- Lead sponsor
- Averto Medical, Inc.
- Industry
- Eligibility
- 22 Years to 75 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Orlando, Florida • Weston, Florida • Columbus, Ohio + 3 more
- Conditions
- Rectal Cancer
- Interventions
- Advanced MR Imaging
- Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
- Interventions
- Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer AJCC v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Colon Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage III Liver Cancer, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Rectal Cancer AJCC v7, Stage III Small Intestinal Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIA Gastric Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIA Small Intestinal Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7, Stage IIIB Gastric Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIB Small Intestinal Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7, Stage IIIC Esophageal Cancer AJCC v7, Stage IIIC Gastric Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Colon Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Liver Cancer, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Rectal Cancer AJCC v7, Stage IV Small Intestinal Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVA Liver Cancer, Stage IVA Rectal Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Stage IVB Liver Cancer, Stage IVB Rectal Cancer AJCC v7
- Interventions
- Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study, Ropidoxuridine
- Radiation · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Colorectal Cancer
- Interventions
- monoclonal antibody A33, carmustine, fluorouracil, streptozocin, vincristine sulfate
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- BRAF V600 Colorectal Cancer
- Interventions
- Dabrafenib, LTT462, Trametinib, LXH254, TNO155, Spartalizumab, Tislelizumab
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
- Conditions
- Rectal Cancer, Breast Cancer, Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
- Interventions
- RMC-6291
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 15
- States / cities
- Springdale, Arkansas • Orange, California • Sacramento, California + 10 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Amifostine trihydrate, Radiation therapy
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Rectal Cancer, Ulcerative Colitis, Familial Adenomatous Polyposis, Diverticulitis
- Interventions
- GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement, Staple line without reinforcement
- Device · Procedure
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 16
- States / cities
- Mobile, Alabama • Los Angeles, California • Weston, Florida + 12 more
- Conditions
- Colorectal Cancer
- Interventions
- everolimus, antiangiogenesis therapy, biopsy, diagnostic procedure, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis, protein tyrosine kinase inhibitor therapy, reverse transcriptase-polymerase chain reaction
- Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Carcinoma, Squamous Cell, Anorectal Cancer
- Interventions
- Pembrolizumab, Lenvatinib
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Malignant Digestive System Neoplasm, Rectal Carcinoma, Small Intestinal Carcinoma
- Interventions
- PAGODA algorithm, Oxaliplatin, Folinic Acid, Fluorouracil
- Other · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 360
- States / cities
- Fairbanks, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 268 more
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV A Bladder Cancer, Stage IV A Rectal Cancer, Stage IV B Colon Cancer, Stage IV B Rectal Cancer
- Interventions
- PET Scan, CT Scan, fludeoxyglucose F 18, computer-aided detection/diagnosis
- Procedure · Radiation
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Colorectal Cancer
- Interventions
- FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 121
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 100 more
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- oxaliplatin, capecitabine, therapeutic conventional surgery, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer
- Interventions
- Expressive writing
- Behavioral
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cholangiocarcinoma, Multiple Myeloma, Colon Cancer, Rectal Cancer
- Interventions
- Return of Genetic Results: Biomarker information from cancer cells, Return of Genetic Results: Inherited mutations related to cancer, Return of Genetic Results: Inherited mutations related to other medical issues
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Colorectal Cancer, Islet Cell Tumor, Liver Cancer, Metastatic Cancer, Neuroendocrine Carcinoma
- Interventions
- isolated perfusion, melphalan, conventional surgery
- Drug · Procedure
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- Not listed
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Rectal Cancer, Rectum
- Interventions
- questionnaires, CSI-SH- Cancer Survivorship Intervention
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2024
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Intracranial Glioma, Metastatic Brain Tumor, Breast Cancer, Neuroendocrine Tumors, Rectal Cancer
- Interventions
- 1-(2-[18F]FLUOROETHYL)-L-Tryptophan
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Detroit, Michigan